1. Home
  2. CELC vs PRM Comparison

CELC vs PRM Comparison

Compare CELC & PRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$53.29

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

PRM

Perimeter Solutions SA

N/A

Current Price

$27.56

Market Cap

4.8B

ML Signal

N/A

Company Overview

Basic Information
Metric
CELC
PRM
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.8B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
CELC
PRM
Price
$53.29
$27.56
Analyst Decision
Strong Buy
Buy
Analyst Count
13
3
Target Price
★ $150.85
$39.33
AVG Volume (30 Days)
920.9K
★ 1.1M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.14
Revenue
N/A
N/A
Revenue This Year
N/A
$34.85
Revenue Next Year
$1,921.71
$10.36
P/E Ratio
★ N/A
$25.71
Revenue Growth
N/A
N/A
52 Week Low
$53.54
$20.38
52 Week High
$151.02
$38.17

Technical Indicators

Market Signals
Indicator
CELC
PRM
Relative Strength Index (RSI) 30.06 41.22
Support Level N/A $25.43
Resistance Level $72.76 $32.32
Average True Range (ATR) 4.24 1.50
MACD -1.03 -0.11
Stochastic Oscillator 0.16 11.68

Price Performance

Historical Comparison
CELC
PRM

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

About PRM Perimeter Solutions SA

Perimeter Group Inc is a provider of industrial products and services that support critical and complex customer missions across a range of niche applications. It comprises six market businesses across two reporting segments: Fire Safety (Perimeter Solutions, Solberg Fire, and Monaco Enterprises) and Specialty Products (PDI, MMT, and IMS). The group prioritizes serving customer needs while driving private-equity-like returns, enabled by its Operational Value Drivers model and decentralized operating structure. Perimeter reinvests in its businesses to strengthen the products and services it provides to customers, and it expects to continue growing organically and through value-creating acquisitions.

Share on Social Networks: